$KRMD

KALBERMATTEN ADAM R purchased $49K of KRMD

KALBERMATTEN ADAM R (President-Chief Commercial Off) purchased 12,500 shares of KORU Medical Systems, Inc. (KRMD) at an average of $3.94 ($3.93–$3.96) across 2 trades on 2026-06-11.

Original reporting
SEC EDGAR · KALBERMATTEN ADAM R
Published Jun 15, 2026, 8:34 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 15, 2026, 8:41 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$KRMD
Bullish
low confidence
Mentioned
$KRMD
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KRMDBullishLow
01

Why it matters

The newest fact is the officer’s open-market purchase details (shares, price range, total value) disclosed via EDGAR.

02

Market read

Provides a fresh, primary-source insider buying datapoint that may slightly influence short-term sentiment toward KRMD.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan; traders may still discount the signal if the buy size is small relative to typical insider activity or if broader company catalysts are absent.

Relevance 4/10Novelty 6/10Timing: Filed 2026-06-15; transaction dated 2026-06-11

Background

The article is an SEC Form 4 insider transaction disclosure for KORU Medical Systems, Inc. (KRMD).

Company-level read

Ticker impact

$KRMDBullishLow confidence
Context

SEC Form 4 shows KRMD President-Chief Commercial Officer bought 12,500 shares open-market at ~$3.94 on 2026-06-11.

Expected impact

Likely limited near-term impact; any effect should be small and fade unless followed by additional disclosures or company-specific news.

Evidence & confidence

Form 4 insider buys are typically incremental signals; the article provides no new operational/financial development beyond the transaction details.

Market effects

No sector-level read-through; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Insider buys can be driven by diversification, liquidity needs, or routine compensation-related activity rather than a bullish view.

Key entities

  • KORU Medical Systems, Inc.

    Company whose insider transaction is disclosed on Form 4.

  • KALBERMATTEN ADAM R

    President-Chief Commercial Officer who purchased KRMD shares.

Related articles

$KRMDMed

KORU Medical Systems Q2 Earnings Call Highlights

KORU Medical Systems (KRMD) reported Q2 PST revenue of $0.6M, down 35% year over year, citing lower clinical-trial orders and timing. Gross margin rose to 65.1% from 63.5%. The company narrowed full-year revenue guidance to $47.5M-$48.5M, raised gross-margin guidance to 62%-64%, ended with $8.3M cash, and expects positive adjusted EBITDA. It acquired a connected monitoring technology asset and shifted some FDA oncology timing.

$KRMDMedAI 8/10

KORU Medical Systems, Inc. Q2 2026 Earnings Call Summary

KORU Medical Systems reported Q2 2026 revenue up 18% and first positive net income since 2019, with domestic revenue up 12% and international revenue up 59%. It withdrew a US FDA 510(k) for Phesgo, narrowed FY revenue guidance to $47.5M-$48.5M, raised gross margin to 62%-64%, and expects positive adjusted EBITDA in 2026.

$KRMDMed

KORU Medical Systems, Inc. (KRMD): Results of Operations and Financial Condition

KORU Medical Systems, Inc. (KRMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99 2 ex_99-1.htm PRESS RELEASE, DATED AUGUST 5, 2026 EXHIBIT 99.1 KORU Medical Systems Announces Second Quarter 2026 Results and Updates Full Year 2026 Guidance MAHWAH, NJ – August 5, 2026 – KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading